Expansions, acquisitions, and agreements were the most adopted growth strategies by key players in the cell dissociation market
The cell dissociation market is expected to reach USD 440.5 million by 2023 from USD 241.2 million in 2017, at a CAGR of 12.8%. Factors driving the growth of this market include the increasing research on chronic disease and rising R&D investments in the pharmaceutical & biotechnology companies.
Download FREE Brochure:
https://www.marketsandmarkets.com/pdfdownload.asp?id=97548003
The cell dissociation market market is consolidated in nature, with a few number of players offering variety of products. The key players in the market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Roche (Switzerland), HiMedia Laboratories (India), and GE Healthcare (US). The other players in the market include Miltenyi Biotec (Germany), Lonza (Switzerland), PAN-Biotech (Germany), ATCC (US), and BD (US).
Most companies in the cell dissociation market adopted expansions, acquisitions, and agreements as the key business growth strategy. These strategies accounted for the largest share of the overall growth strategies mapped from 2014 to 2017. Some of the leading players who adopted these strategies include Thermo Fisher Scientific (US) and Merck KGaA (Germany).
Thermo Fischer Scientific held the leading position in the cell dissociation market in 2017. The company has a strong product portfolio. The company offers enzymatic and non-enzymatic dissociation products. In order to strengthen its position, the company mainly focuses on the expansion of its business channels. For instance, in 2016, the company opened its new global headquarters at 168 Third Avenue in Massachusetts (US).
Merck KGaA ranked second in the cell dissociation market in 2017. The company has a wide range of enzymatic, non-enzymatic dissociation and instrument product portfolio. The company adopted acquisitions and expansions as key strategies in order to strengthen its position in the market. For instance, in 2015, Merck acquired Sigma-Aldrich to enhance its life sciences related product portfolio. Similarly, in 2016, Merck opened a new Life Science Center at Massachusetts (US).
Roche held the third position in the cell dissociation market in 2017. The companies leading position is due to its strong geographical presence as well as its brand image in the market. Moreover, the company offers cell dissociation enzyme products in customized quantities.
Know More:
https://www.marketsandmarkets.com/Market-Reports/cell-dissociation-market-97548003.html
The cell dissociation market is expected to reach USD 440.5 million by 2023 from USD 241.2 million in 2017, at a CAGR of 12.8%. Factors driving the growth of this market include the increasing research on chronic disease and rising R&D investments in the pharmaceutical & biotechnology companies.
Download FREE Brochure:
https://www.marketsandmarkets.com/pdfdownload.asp?id=97548003
Most companies in the cell dissociation market adopted expansions, acquisitions, and agreements as the key business growth strategy. These strategies accounted for the largest share of the overall growth strategies mapped from 2014 to 2017. Some of the leading players who adopted these strategies include Thermo Fisher Scientific (US) and Merck KGaA (Germany).
Thermo Fischer Scientific held the leading position in the cell dissociation market in 2017. The company has a strong product portfolio. The company offers enzymatic and non-enzymatic dissociation products. In order to strengthen its position, the company mainly focuses on the expansion of its business channels. For instance, in 2016, the company opened its new global headquarters at 168 Third Avenue in Massachusetts (US).
Merck KGaA ranked second in the cell dissociation market in 2017. The company has a wide range of enzymatic, non-enzymatic dissociation and instrument product portfolio. The company adopted acquisitions and expansions as key strategies in order to strengthen its position in the market. For instance, in 2015, Merck acquired Sigma-Aldrich to enhance its life sciences related product portfolio. Similarly, in 2016, Merck opened a new Life Science Center at Massachusetts (US).
Roche held the third position in the cell dissociation market in 2017. The companies leading position is due to its strong geographical presence as well as its brand image in the market. Moreover, the company offers cell dissociation enzyme products in customized quantities.
Know More:
https://www.marketsandmarkets.com/Market-Reports/cell-dissociation-market-97548003.html
No comments:
Post a Comment